| Literature DB >> 21695115 |
Dirk H Mueller1, Douglas Lungu, Arnab Acharya, Natasha Palmer.
Abstract
Increasingly seen as a useful tool of health policy, Essential or Minimal Health Packages direct resources to interventions that aim to address the local burden of disease and be cost-effective. Less attention has been paid to the delivery mechanisms for such interventions. This study aimed to assess the degree to which the Essential Health Package (EHP) in Malawi was available to its population and what health system constraints impeded its full implementation. The first phase of this study comprised a survey of all facilities in three districts including interviews with all managers and clinical staff. In the second and third phase, results were discussed with District Health Management Teams and national level stakeholders, respectively, including representatives of the Ministry of Health, Central Medical Stores, donors and NGOs. The EHP in Malawi is focussing on the local burden of disease; however, key constraints to its successful implementation included a widespread shortage of staff due to vacancies but also caused by frequent trainings and meetings (only 48% of expected man days of clinical staff were available; training and meetings represented 57% of all absences in health centres). Despite the training, the percentage of health workers aware of vital diagnostic and therapeutic approaches to EHP conditions was weak. Another major constraint was shortages of vital drugs at all levels of facilities (e.g. Cotrimoxazole was sufficiently available to treat the average number of patients in only 27% of health centres). Although a few health workers noted some improvement in infrastructure and working conditions, they still considered them to be widely inadequate. In Malawi, as in similar resource poor countries, greater attention needs to be given to the health system constraints to delivering health care. Removal of these constraints should receive priority over the considerable focus on the development and implementation of essential packages of interventions.Entities:
Mesh:
Year: 2011 PMID: 21695115 PMCID: PMC3114780 DOI: 10.1371/journal.pone.0020741
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Conceptual framework – supplying health care in Malawi.
Study design.
| Selection of Districts | ||
| Nsanje | Nkhotokota | Rumphi |
| densely populated; difficult access to and within district (no tarmac, parts cut off during rainy season); southern most district – long distance from the capital; hot climate. | mid-level density; major tarmac road leading through it; most facilities within short distance to tarmac; long lake shore; easy access to the capital (2 hrs. drive); distinct burden of disease. | sparsely populated; district capital easily accessible but not other areas; moderate climate; Iong distance to capital but easily accessible (tarmac) |
| Description of Phases | Description | Distinct Feature |
| Phase I | Survey at the facility level, including interviews with health workers and the facility manager; All facilities visited (54 facilities with 136 health worker interviews) | 37 rural health centres without maternity; 7 rural health centres with maternity service; 6 community rural hospitals; 3 district hospitals; 1 reproductive health care centre (NGO-operated) |
| Phase II | Solicitation of response to a presentation of findings in Phase I from the District Health Management Team (DHMT) and district health staff | Separate sessions for district health staff away from DHMT |
| Phase III | Key stakeholder interviews at the national level | Summary of findings in Phase I and II were sent before the interviews |
Percent of health centres (HC, n = 45) or hospitals (n = 9) which keep key drugs sufficient, insufficient or not at all in stock at the time of the survey (“sufficient” defined as the quantity deemed necessary by the pharmacist/facility manager to treat the average caseload that required this drug during the forthcoming 3 months; differences between HC and hospitals not statistically significant).
| Sufficient stock for 3 months to come | Insufficient stock for 3 months to come | Out of stock | ||||
| Drug | HC | Hospitals | HC | Hospitals | HC | Hospitals |
| Paracetamol | 11% | 22% | 76% | 78% | 13% | 0% |
| Aspirin | 18% | 33% | 69% | 67% | 13% | 0% |
| Diazepam | 16% | 33% | 56% | 67% | 29% | 0% |
| ORT | 18% | 22% | 29% | 56% | 53% | 22% |
| Nystatin oral drops | 24% | 33% | 58% | 56% | 18% | 11% |
| Chlorhexidine | 36% | 44% | 27% | 44% | 38% | 11% |
| Calamine lotion | 44% | 33% | 38% | 56% | 18% | 11% |
| Gentiana violet (GV) | 51% | 22% | 31% | 67% | 18% | 11% |
| Hydralazine | 9% | 0% | 18% | 56% | 73% | 44% |
| Cotrimoxazole | 27% | 44% | 60% | 56% | 13% | 0% |
| Metronidazole | 18% | 56% | 62% | 44% | 20% | 0% |
| Benz. Penicilline | 24% | 33% | 62% | 67% | 13% | 0% |
| Erythromycine caps. | 22% | 67% | 58% | 33% | 20% | 0% |
| SP 500 | 42% | 33% | 56% | 67% | 2% | 0% |
| Quinine tablets | 20% | 11% | 62% | 89% | 18% | 0% |
| Quinine injectable | 47% | 67% | 42% | 33% | 11% | 0% |
| Lidocain | 24% | 11% | 22% | 33% | 53% | 56% |
| Syntometrine | 42% | 44% | 38% | 56% | 20% | 0% |
| Vitamin A | 29% | 11% | 22% | 22% | 49% | 67% |
| Magnesium sulphate | 18% | 56% | 16% | 11% | 67% | 33% |
Percentage of expected positions filled by district and hc/hospitals (expected positions based on facility managers' and District Health Offices' information); HC n = 45, hospitals n = 9.
| Nkhotakota | Nsanje | Rumphi | ||||
| HC | Hospitals | HC | Hospitals | HC | Hospitals | |
| Physicians | 50% | 50% | n/a | 33% | n/a | 33% |
| Clinical Officers | 67% | 100% | n/a | 52% | 100% | 37% |
| Medical Assistants | 91% | 100% | 67% | 73% | 68% | 65% |
| Regist. Nurses | 56% | 88% | n/a | 33% | n/a | 29% |
| Enr. Nurses | 56% | 78% | 53% | 56% | 41% | 60% |
Number of days absent per health worker (and percentage of total workdays) during 3 months by reason (n = total numbers of filled positions across all visited facilities).
| Physicians,n = 10 | Clin. Officers, n = 52 | Med. Assistants, n = 66 | Reg. Nurses, n = 27 | Enr. Nurses, n = 230 | |
| Leave | 2.0 (3%) | 3.8 (5%) | 2.6 (4%) | 2.6 (4%) | 2.4 (3%) |
| Training | 0.9 (1%) | 3.1 (4%) | 4.1 (6%) | 6.6 (9%) | 3.2 (5%) |
| Meetings | 3.7 (5%) | 3.0 (4%) | 1.9 (3%) | 2.3 (3%) | 1.1 (2%) |
| Sick | 0.2 (0.3%) | 0.5 (1%) | 0.9 (1%) | 2.9 (4%) | 0.9 (1%) |
| Relief and other reasons | 0.5 (1%) | 2.2 (3%) | 2.2 (3%) | 1.6 (2%) | 1.6 (2%) |
| Total | 7.3 (100%) | 12.5 (100%) | 11.7 (100%) | 16.0 (100%) | 9.3 (100%) |
Percentage of health workers that mention selected key aspects for assessment and treatment of malaria, ARI, OI and obstetric complications (by hc/hospitals), n = total number of respondents, number of respondents to obstetric questions (with obstetric experience).
| Health Centres | Hospitals | Total | |
| n = 95,62 | n = 36,25 | n = 131,87 | |
| Malaria in children <5 assessment | |||
| Anaemia | 72% | 83% | 75% |
| Blood film | 96% | 97% | 96% |
| Malaria in children <5 treatment | |||
| SP | 98% | 100% | 98% |
| Quinine | 94% | 100% | 95% |
| Acute respiratory tract infections (ARI) assessment | |||
| respiratory rate | 47% | 58% | 50% |
| chest movements | 69% | 72% | 70% |
| Acute respiratory tract infections (ARI) treatment | |||
| Antibiotic Rx: Cotrimox., Xpen, Chloramphenicol | 63% | 81% | 68% |
| Opportunistic Infections (OI) assessment: Zoster | |||
| Dermatome distribution of symptoms | 37% | 69% | 46% |
| Opportunistic Infections (OI) assessment: Kaposi Sarkoma | |||
| Lesions on skin/in mouth | 24% | 42% | 29% |
| Opportunistic Infections (OI) treatment: Zoster | |||
| Analgesics | 77% | 89% | 81% |
| Acyclovir | 30% | 69% | 41% |
| Maternal Health (MH) assessment: Post-partum haemorrhage (PPH) | |||
| Vital signs | 53% | 64% | 56% |
| Contracted uterus? | 58% | 68% | 61% |
| Maternal Health (MH) assessment: Retained placenta | |||
| Bladder empty? | 22% | 20% | 21% |
| Cervix open | 12% | 8% | 11% |
| Maternal Health (MH) assessment: Eclampsia | |||
| Vital signs/blood pressure | 80% | 80% | 80% |
| Protein in urine? | 53% | 76% | 60% |
| Maternal Health (MH) treatment: Post-partum haemorrhage (PPH) | |||
| bi-manual compression | 5% | 8% | 6% |
| Pitocin | 23% | 56% | 33% |
| Maternal Health (MH) treatment: Retained placenta | |||
| Empty bladder | 25% | 16% | 22% |
| Manual removal | 53% | 76% | 60% |
| Maternal Health (MH) treatment: Eclampsia | |||
| MgSO4 | 22% | 80% | 39% |
| Hydralazine | 13% | 32% | 19% |
Selection of key aspects (not exhaustive).